Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.
Bilayer Therapeutics's investors include Kendall Capital Partners, Diamond Biofund Inc..
Bilayer Therapeutics is headquartered in Cambridge, United States.
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.
Bilayer Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bilayer Therapeutics — Funding & Investors." VCBacked, January 1, 2022, https://www.vcbacked.co/company/bilayer-therapeutics. Accessed November 17, 2026.
VCBacked. (2022). Bilayer Therapeutics — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/bilayer-therapeutics
{{cite web |title=Bilayer Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bilayer-therapeutics |website=VCBacked |access-date=November 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Bilayer Therapeutics? Request a listing update